Redwire and Red Cat partner on drone integration for U.S. Army missions
Investing.com - Advanced Medical Solutions Group (LON:AMS) reported robust first half results, with revenue jumping 66% YoY to £110.8 million, driven by the acquisition of Peters Surgical and solid organic growth of 12.5%.
The company’s shares rose 4.6% following the announcement as investors responded positively to the maintained momentum and outlook.
The medical technology company saw its Advanced Woundcare segment grow 17% (18% at constant exchange rates), while the Surgical business increased 10.7%.
US LiquiBand products continued their recent momentum with 14% growth (18% at constant exchange rates), and Biosurgical products surged 37% (40% at constant exchange rates) due to yield improvements following last year’s Syntacoll acquisition.
EBITDA increased 44% in the first half, though margins declined to 22.0% from 25.3% due to the consolidation of Peters Surgical, which was acquired in the second half of 2024.
The company benefited from improved Woundcare margins following a first quarter restructuring, growth in high-margin US LiquiBand products, and enhanced Biosurgical manufacturing yields.
The company confirmed that the Peters Surgical integration is proceeding well with commercial synergies beginning to materialize. Management maintained its full-year guidance, in line with market expectations, and anticipates US launches in Biosurgical and Sutures later in 2025.
"We’re pleased with our continued momentum across all business segments," said a company executive. "The integration of Peters Surgical is yielding positive results, and we remain confident in our growth trajectory for the remainder of the year."
The Board proposed a 10% increase in the interim dividend compared to the first half of 2024, and expects leverage to fall to approximately 1x by the end of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.